Optimization of Visual Field Perimetry With Artificial Intelligence
Launched by SIGHT INTELLIGENCE ENGINEERING CORPORATION · Apr 2, 2025
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving a test called visual field perimetry, which helps detect issues with vision, particularly related to glaucoma. The goal is to gather visual field data from healthy adults to create a new and better test that uses advanced technology, including Artificial Intelligence (AI), to ensure it accurately measures vision.
To participate in the study, individuals must be healthy adults aged 18 years or older, with good vision (20/40 or better) and a normal-looking optic nerve. Participants will be asked to wear a Virtual Reality Headset for about 10 minutes while their vision data is collected. Afterward, they may complete a brief questionnaire about their experience. It's important to note that this trial is not yet recruiting participants, and anyone with certain eye conditions or significant health issues will not be eligible.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy adults aged 18 years or older.
- • Best corrected visual acuity of 20/40 or better in each eye.
- • Normal optic nerve appearance upon clinical examination.
- Exclusion Criteria:
- • Best corrected visual acuity worse than 20/40.
- • Cup-to-disc ratio greater than 0.5.
- • Previously documented glaucoma or optic neuropathy.
- • Any significant ocular or neurological condition that may impact visual field.
- • Inability to comply with study procedures.
About Sight Intelligence Engineering Corporation
Sight Intelligence Engineering Corporation is a pioneering clinical trial sponsor dedicated to advancing ocular health through innovative research and technology. With a focus on developing cutting-edge solutions for the diagnosis and treatment of eye disorders, the corporation leverages its expertise in engineering and clinical methodologies to design and implement rigorous clinical trials. Committed to improving patient outcomes, Sight Intelligence collaborates with healthcare professionals and regulatory bodies to ensure the highest standards of safety and efficacy in all its studies. Through its dedication to scientific excellence and patient care, the corporation aims to make significant contributions to the field of ophthalmology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported